Although implantable cardioverter-defibrillators (ICDs) are recommended to prevent cardiac death in selected patients with left ventricular systolic dysfunction (LVSD),[@b1] controversies remain about the outcomes of this therapy in important patient subgroups, including women and elderly patients. The clinical trials that support existing guideline recommendations for primary-prevention ICD therapy[@b2]--[@b4] enrolled relatively few women and patients who were younger than those typically seen in clinical practice.[@b5] Studies of age and sex differences in outcomes have focused primarily on overall risks of death, with less attention to broader outcomes including hospitalizations; have assessed short-term outcomes; or have enrolled patients from single centers, limiting generalizability.[@b6]--[@b12] Furthermore, the published literature has not explored the extent to which age and sex differences in outcomes vary according to measures of heart failure severity.

Accordingly, we studied outcomes in the Cardiovascular Research Network (CVRN) Longitudinal Study of Implantable Cardioverter-Defibrillators (LS-ICD), a contemporary community-based cohort receiving ICD therapy for primary prevention, with a focus on death, hospitalization, and complications in women and older patients. Our objectives were to characterize the risks of adverse outcomes in this cohort; to understand sex- and age-related differences in these outcomes; and to determine whether sex- and age-related differences vary as a function of characteristics of heart failure, including etiology, symptom burden, and severity of LVSD.

Methods
=======

Data Sources
------------

The CVRN LS-ICD has been described in detail previously.[@b5] The data for this study were derived from 2 sources. Data on ICD eligibility, clinical characteristics, and device and provider details were collected from the National Cardiovascular Data Registry (NCDR) ICD Registry, a national registry that was formed as part of a coverage-with-evidence requirement of the Centers for Medicare and Medicaid Services.[@b13] The NCDR implements a rigorous data-quality program that includes data and range checks, outlier analysis, and random audits.[@b14] Data on outcomes including device-related complications, hospitalization, and death were obtained from the CVRN Virtual Data Warehouse (VDW), a standardized repository of clinically enriched administrative data generated in a distributed fashion using identical protocols at each participating health plan.[@b15] Institutional review boards at participating sites approved the study. Waiver of informed consent was obtained because of the nature of the study. F.A.M., L.M.R., and K.A.G. had access to and affirm the accuracy of all data.

Study Cohort
------------

We identified 3649 consecutive adult patients (aged \>18 years) undergoing first-time ICD implantation for the primary prevention of sudden cardiac death in 15 hospitals within 7 integrated health systems in the CVRN between January 1, 2006, and December 31, 2010. We excluded patients not enrolled in 1 of the 7 CVRN health plans at the time of implantation (n=610) and those with a left ventricular ejection fraction (LVEF) \>0.35 (n=85). The study cohort, when compared with patients not enrolled, were older on average (median age 69 versus 67 years, *P*\<0.001), included a lower proportion of women (25.8% versus 30.2%, *P*=0.02), were more often white (63.0% versus 43.7%, *P*\<0.001), and had New York Heart Association (NYHA) I to II symptoms more often (61.5% versus 49.3%, *P*\<0.001).

Outcomes
--------

The end points included time to death from any cause, time to hospitalization from any cause and from heart failure, and device-related complications within the first 90 days after implantation. Death was ascertained through the VDW, which uses health system databases, Social Security Administration vital status files, and state death certificate registries, depending on the participating CVRN site. Hospitalizations were assessed using the VDW, which includes admission and discharge dates and diagnoses for all hospitalizations. Because health plans are responsible for coverage of all health services for members, hospitalizations outside of health plan facilities are included in the VDW. Hospitalizations for heart failure were identified using the principal discharge diagnosis for heart failure (Table[1](#tbl1){ref-type="table"}), an approach that has been applied widely in studies of heart failure.[@b16] Follow-up for death and hospitalization was obtained through December 31, 2011, providing up to 6 years of follow-up.

###### 

ICD-9-CM, CPT, and HCPSC Codes Used to Ascertain Clinical Events in the Cardiovascular Research Network Virtual Data Warehouse

  Clinical Event (Ascertainment Time Frame)                                                                               Codes
  ----------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------
  Heart failure hospitalization[\*](#tf1-2){ref-type="table-fn"} (3 years)                                                428-428.99, 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93
  Pneumothorax/hemothorax requiring chest tube (30 days)                                                                  ICD-9-CM 512.x or 511.8 AND
  ICD-9 Procedure 34.04, 34.05, 34.06, or 34.09                                                                           
  Hematoma requiring transfusion or evacuation (30 days)                                                                  ICD-9-CM 998.1x, 287.4x, 518.7, V58.2, or V59.01 AND
  ICD-9 Procedure 99.00, 99.03. 99.04, 34.04, or 34.09                                                                    
  Tamponade or pericardiocentesis (30 days)                                                                               ICD-9-CM 420, 423.0, 423.3, or 423.9 AND
  ICD-9-CM Procedure 37.0 or 37.12                                                                                        
  Mechanical complication of ICD with system revision (90 days)                                                           ICD-9-CM 996.0x AND
  ICD-9-CM Procedure 37.75, 37.79, 37.97, 37.99, 00.52, or 37.95 OR CPT 33215, 33225, 33233, 33235, 71090, 33224, 33242   
  OR HCPCS C1777, C1895, C1898, C1900, C1899, G0299, G0300                                                                
  ICD Re-implantation (90 days)                                                                                           ICD-9-CM Procedure 00.52, 00.50, 00.51, 00.53, 00.54, 37.94, 37.89, 37.96, 37.98 OR
  CPT 33216, 33217, 33218, 33220, 33223, 33240, 33241, 33249, 33207, 33208, 33214, 33226, 33243, 33244 OR                 
  HCPCS C1721, C1722, C1785, C1786, C1882, C1882                                                                          
  Device related infection (90 days)                                                                                      ICD-9-CM 996.61

CPT indicates Current Procedural Terminology Codes; HCPCS, Healthcare Common Procedure Coding System; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification.

To ascertain hospitalizations attributed to heart failure, only the principal discharge diagnosis was considered.

Device-related complications were ascertained using a modification of the approach developed for purposes of reporting complications after ICD implantation used for hospital public reporting.[@b17] This approach applies a variable ascertainment time frame (either 30 or 90 days) depending on the complication. We identified events using codes from the *International Classification of Diseases, Ninth Revision, Clinical Modification*; the Current Procedural Terminology; and the Healthcare Common Procedure Coding System, in any position on an inpatient claim (Table[1](#tbl1){ref-type="table"}). Complications ascertained over the first 30 days after ICD implantation included pneumothorax or hemothorax requiring a chest tube, hematoma requiring transfusion or evacuation, cardiac tamponade or pericardiocentesis, or death. Complications ascertained over the first 90 days included device-related infection and mechanical complications of the ICD requiring system revision and device reimplantation. Those patients with incomplete follow-up data for the complications end point (n=72) were excluded from the complications analysis.

Covariates
----------

Patient characteristics included demographics (age, sex, and race or ethnicity), cardiovascular history (NYHA class, LVEF, ischemic heart disease, nonischemic cardiomyopathy, atrial fibrillation), noncardiovascular comorbidities, laboratory values (blood urea nitrogen, hemoglobin, and creatinine) at the time of implantation, electrocardiographic findings (QRS morphology and duration), and device type. For the death and hospitalization end points, we also considered the prescription of medications for heart failure known to influence heart failure outcomes (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta blockers, and aldosterone antagonists) at hospital discharge. To avoid case-wise deletion, missing values were imputed using approaches that varied based on the proportion of missing values. Variables were generally missing infrequently (\<2.2%); in these cases, continuous variables were imputed using the median value of known measurements in the population, and categorical variables were imputed as the most common response in the population. Because QRS morphology and QRS duration were missing more frequently (12%), a dummy variable for missing status was used in structuring these variables as candidates for the multivariable models.[@b18]

Statistical Analysis
--------------------

Baseline data are presented as proportions for categorical variables and as means with SDs for continuous variables. Comparisons of variables in sex and age strata were performed using chi-square tests for categorical variables and Student *t* tests for continuous variables. For the death and hospitalization outcomes, crude rates of events were calculated per 1000 person-years of follow-up with associated 95% CIs. Time-to-event analysis was performed with log-rank tests to compare actuarial survival rates between respective comparison groups.

Four separate multivariable models (1 per study outcome) were constructed. Bivariate associations with *P*\<0.20 were included in multivariable analyses after removing any potentially collinear variables. In each case, collinearity among candidate variables was examined using eigenvalues obtained through principal component analysis. From the principal component results, conditional indices \>3 were considered potentially collinear. The corresponding covariates were examined for collinearity in the multivariable model. If including both covariates resulted in instability in estimates or variance, the variable with the stronger bivariate association with the outcome was retained as a candidate. For death and the hospitalization outcomes, multivariable survival analysis was performed using Cox proportional hazards regression. In Cox models for death, patients were censored at the time of last documented encounter regardless of the continuity of health plan enrollment; for the hospitalization outcome, patients were censored at the time of first health plan disenrollment or death. All multivariable models accounted for the clustering of patients by site. For hospitalizations, a random-site effect was included in the multivariable Cox models. For mortality, a fixed-site effect was included in the multivariable Cox models because of lack of convergence of a random-effects model. For complications, generalized estimating equations were used in logistic models, with site treated as a random effect.

In all multivariable models, age, sex, LVEF, NYHA symptom status, and etiology of LVSD were included. To test for variability in relationships of age and sex to these outcomes, interaction terms between either age or sex with 3 dichotomous variables reflecting heart failure status (NYHA class I to II versus III to IV, LVEF \<0.30 versus 0.30 to 0.35, and ischemic versus nonischemic etiology) were tested individually within the outcome models in which a significant primary age or sex association was identified. A 2-sided *P* value \<0.05 was considered statistically significant. All tests were 2-sided. We used SAS version 9.2 and 9.3 (SAS Institute Inc) for all analyses.

Role of the Funding Source
--------------------------

This study was funded by the Agency for Healthcare Research and Quality; the National Heart, Lung, and Blood Institute of the NIH; and the American College of Cardiology Foundation. The study was reviewed and approved by the research and publications committee of the NCDR ICD Registry.

Results
=======

Study Population
----------------

The study population consisted of 2954 patients receiving an ICD for primary prevention; 769 (26.0%) were women, and 1827 (61.8%) were aged \>65 years (Table[2](#tbl2){ref-type="table"}). Compared with men, women were less frequently white (58.5% versus 64.3%, *P*\<0.001), more likely to have advanced heart failure symptoms (48.0% with NYHA classification III or IV versus 35.2%, *P*\<0.001), less likely to have a history of atrial fibrillation (23.5% versus 35.1%, *P*\<0.001), and less likely to have ischemic cardiomyopathy (44.1% versus 68.5%, *P*\<0.001).

###### 

Study Population Characteristics and According to Sex and Age

  Characteristic                        Total (n=2954)      Women (n=769)       Men (n=2185)        *P* Value   Age ≤65 Years (n=1127)   Age \>65 Years (n=1827)   *P* Value
  ------------------------------------- ------------------- ------------------- ------------------- ----------- ------------------------ ------------------------- -----------
  Aged \>65 years                       1828 (61.9%)        473 (61.5%)         1354 (62.0%)        0.82        ---                      ---                       
  Age, y, median (IQR)                  69.0 (60.0, 75.0)   68.0 (60.0, 75.0)   69.0 (60.0, 75.0)   0.32        57.0 (51.0 to 62.0)      74.0 (70.0 to 78.0)       NA
  Female                                769 (26.0%)         ---                 ---                 ---         296 (26.3%)              473 (25.9%)               0.82
  Race/ethnicity                                                                                    \<0.001                                                        \<0.001
   White                                1856 (62.8%)        450 (58.5%)         1406 (64.3%)                    611 (54.2%)              1245 (68.1%)              
   Black                                463 (15.7%)         163 (21.2%)         300 (13.7%)                     231 (20.5%)              232 (12.7%)               
   Hispanic (not black)                 438 (14.8%)         108 (14.0%)         330 (15.1%)                     184 (16.3%)              254 (13.9%)               
   Other                                197 (6.7%)          48 (6.2%)           149 (6.8%)                      101 (9.0%)               96 (5.3%)                 
  NYHA class                                                                                        \<0.001                                                        \<0.001
   I to II                              1809 (61.2%)        397 (51.6%)         1412 (64.6%)                    740 (65.7%)              1069 (58.5%)              
   III to IV                            1139 (38.6%)        369 (48.0%)         770 (35.2%)                     386 (34.3%)              753 (41.2%)               
  LVEF, %                                                                                           0.62                                                           0.12
   31 to 35                             431 (14.6%)         108 (14.0%)         323 (14.8%)                     150 (13.3%)              281 (15.4%)               
   ≤30                                  2523 (85.4%)        661 (86.0%)         1862 (85.2%)                    977 (86.7%)              1546 (84.6%)              
  Etiology of cardiomyopathy                                                                        \<0.001                                                        \<0.001
   Ischemic                             1863 (62.2%)        339 (44.1%)         1497 (68.5%)                    556 (49.3%)              1280 (70.1%)              
   Nonischemic                          1118 (37.8%)        430 (55.9%)         688 (31.5%)                     571 (50.7%)              547 (29.9%)               
  Atrial fibrillation                   948 (32.1%)         181 (23.5%)         767 (35.1%)         \<0.001     254 (22.5%)              694 (38.0%)               \<0.001
  Diabetes mellitus                     1246 (42.2%)        312 (40.6%)         934 (42.7%)         0.40        459 (40.7%)              787 (43.1%)               0.43
  Hypertension                          2168 (73.4%)        550 (71.5%)         1618 (74.1%)        0.39        713 (63.3%)              1455 (79.6%)              \<0.001
  Chronic lung disease                  590 (20.0%)         172 (22.4%)         418 (19.1%)         0.13        191 (16.9%)              399 (21.8%)               0.004
  Left bundle branch block              825 (27.9%)         318 (41.4%)         507 (23.2%)         \<0.001     270 (24.0%)              555 (30.4%)               \<0.001
  QRS duration \>0.12 s                 1450 (49.1%)        419 (54.5%)         1031 (47.2%)        \<0.001     416 (36.9%)              1034 (56.6%)              \<0.001
  Creatinine, mg/dL                     1.4 (0.9)           1.2 (0.7)           1.4 (1.0)           \<0.001     1.3 (1.03)               1.4 (0.81)                0.015
  Blood urea nitrogen, mg/dL            24.9 (13.84)        23.9 (13.65)        25.2 (13.89)        0.019       22.5 (12.99)             26.3 (14.14)              \<0.001
  Estimated GFR, mL/min per 1.72 m^2^   61.5 (22.5)         59.3 (22.9)         62.3 (22.3)         0.001       71.6 (23.9)              55.3 (19.1)               \<0.001
  Hemoglobin, g/L                                                                                   \<0.001                                                        \<0.001
   \>14.5                               687 (23.3%)         56 (7.3%)           631 (28.9%)                     333 (29.5%)              354 (19.4%)               
   13.3 to 14.5                         754 (25.5%)         164 (21.3%)         590 (27.0%)                     291 (25.8%)              463 (25.3%)               
   12.1 to 13.2                         689 (23.3%)         259 (33.7%)         430 (19.7%)                     241 (21.4%)              448 (24.5%)               
   \<12.1                               759 (25.7%)         276 (35.9%)         483 (22.1%)                     235 (20.9%)              524 (28.7%)               
  Medications                                                                                                                                                      
   ACE inhibitor or ARB                 2554 (86.5%)        675 (87.8%)         1879 (86.0%)        0.21        989 (87.8%)              1565 (85.7%)              0.11
   Beta blocker                         2690 (91.1%)        704 (91.5%)         1986 (90.9%)        0.48        1048 (93.0%)             1642 (89.9%)              0.02
   Aldosterone antagonist               994 (33.6%)         286 (37.2%)         708 (32.4%)         0.02        436 (38.7%)              558 (30.5%)               \<0.001
  Device type                                                                                       \<0.001                                                        \<0.001
   Single chamber                       955 (32.3%)         220 (28.6%)         735 (33.6%)                     494 (43.8%)              461 (25.2%)               
   Dual chamber                         1062 (36.0%)        235 (30.6%)         827 (37.8%)                     352 (31.2%)              710 (38.9%)               
   CRT-D                                937 (31.7%)         314 (40.8%)         623 (28.5%)                     281 (24.9%)              656 (35.9%)               

ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CRT-D, cardiac resynchronization therapy with defibrillator; GFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.

Compared with younger patients, those aged \>65 years were more likely to have advanced heart failure symptoms (41.2% versus 34.3%, *P*\<0.001); were more frequently white (68.1% versus 54.2%, *P*\<0.001); and had a higher prevalence of coexisting conditions, including atrial fibrillation (38.0% versus 22.5%, *P*\<0.001), hypertension (79.6% versus 63.3%, *P*\<0.001), and chronic lung disease (21.8% versus 16.9%, *P*\<0.001). Older patients were more likely to have ischemic cardiomyopathy (70.1% versus 49.3%, *P*\<0.001). There were no significant difference in age between men and women (Table[2](#tbl2){ref-type="table"}).

Outcomes
--------

The crude incidence rates, unadjusted risks, and adjusted risks for adverse outcomes in the total cohort and in patients further stratified by age and sex are shown in Table[3](#tbl3){ref-type="table"}. The median duration of enrollment was 2.4 years (interquartile range 1.3 to 3.8 years). The incidence rate of death was 110 per 1000 patient-years, which was lower in women compared with men (crude incidence 86 versus 118, adjusted hazard ratio \[HR\] 0.67, 95% CI 0.56 to 0.80) and higher in patients aged \>65 years compared with younger patients (crude incidence 133 versus 67, adjusted HR 1.55, 95% CI 1.30 to 1.86). The incidence rate of all-cause hospitalization was 438 per 1000 patient-years and did not differ significantly between men and women or between younger and older patients. The incidence rate of hospitalization for heart failure was 111 per 1000 patient-years, which was lower in women compared with men (crude incidence rates 102 versus 115, adjusted HR 0.82, 95% CI 0.68 to 0.98) and higher in older compared with younger patients (crude incidence rates 127 versus 84, adjusted HR 1.25, 95% CI 1.05 to 1.49). The overall proportion of patients who developed any device-related complication was 8.36% and was higher in women than in men (crude proportions 10.74% versus 7.52%, adjusted odds ratio 1.38, 95% CI 1.01 to 1.90). With respect to individual complications, women had a significantly higher risk of tamponade (1.89% versus 0.47%, *P*\<0.001); the sex differences in risks of other complications were not statistically significant (Table[4](#tbl4){ref-type="table"}). Older patients had a significantly higher risk of hematoma requiring evacuation or transfusion compared with younger patients (1.01% versus 0.27%, *P*=0.03). The rates of complications varied by device type (single lead 4.63%, dual lead 8.34%, and cardiac resynchronization therapy--defibrillator 12.20%; *P*\<0.001) and were generally higher in women than in men across device types, although the device-specific differences in complications by sex were statistically significant among single-lead devices (Table[5](#tbl5){ref-type="table"}). None of the comparisons of the differences in complication rates by device were statistically significant between age groups. The rates of individual complications by device type are presented in Table[6](#tbl6){ref-type="table"}.

###### 

Event Rates and Risk Ratios According to Age and Sex

  Event                                                                All     Sex      Age, y                                                                                     
  -------------------------------------------------------------------- ------- -------- -------- --------------------- --------------------- ------- ------- --------------------- ---------------------
  Death[\*](#tf3-2){ref-type="table-fn"}                               110     86       118      0.73 (0.61 to 0.86)   0.67 (0.56 to 0.80)   67      133     1.91 (1.62 to 2.26)   1.55 (1.30 to 1.86)
  Hospitalization for all causes[\*](#tf3-2){ref-type="table-fn"}      438     421      445      0.95 (0.86 to 1.06)   0.93 (0.83 to 1.05)   370     480     1.25 (1.13 to 1.38)   1.07 (0.96 to 1.18)
  Hospitalization for heart failure[\*](#tf3-2){ref-type="table-fn"}   111     102      114      0.91 (0.77 to 1.08)   0.82 (0.68 to 0.98)   84      127     1.41 (1.19 to 1.66)   1.25 (1.05 to 1.49)
  Complications[†](#tf3-3){ref-type="table-fn"}                        8.36%   10.74%   7.52%    1.43 (1.12 to 1.96)   1.38 (1.01 to 1.90)   7.15%   9.10%   1.30 (0.98 to 1.72)   1.17 (0.86 to 1.59)

Fully adjusted multivariable models included the following variables for each outcome in addition to accounting for clustering of patients by Cardiovascular Research Network site. Death: left ventricular ejection fraction, etiology of cardiomyopathy (ischemic vs non-ischemic), New York Heart Association symptom classification, blood urea nitrogen, atrial fibrillation, diabetes, hypertension, chronic lung disease, hemoglobin, QRS duration, ICD device type, ACE/ARB therapy, and beta blocker. All-cause hospitalization: left ventricular ejection fraction, etiology of cardiomyopathy (ischemic vs nonischemic), New York Heart Association symptom classification, race, atrial fibrillation, diabetes, hypertension, lung disease, estimated glomerular filtration rate, blood urea nitrogen, hemoglobin, ICD device type, QRS duration, ACE/ARB therapy, and beta blocker. Heart failure hospitalization: left ventricular ejection fraction, etiology of cardiomyopathy (ischemic vs nonischemic), New York Heart Association symptom classification, race, atrial fibrillation, diabetes, hypertension, lung disease, estimated glomerular filtration rate, blood urea nitrogen, hemoglobin, ICD device type, QRS duration, ACE/ARB therapy, and aldosterone antagonist. Complications: left ventricular ejection fraction, etiology of cardiomyopathy (ischemic vs non-ischemic), New York Heart Association symptom classification, atrial fibrillation, diabetes, blood urea nitrogen, hemoglobin, ICD device type, left bundle branch block, and QRS duration. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ICD, implantable cardioverter-defibrillator.

Rates expressed as incidence per 1000 patient-years; ratios expressed as hazard ratios with 95% CIs.

Rates expressed as proportions; ratios expressed as odds ratios with 95% CIs.

###### 

Rates of Individual Device-Related Complications by Sex and Age

  Complication                                                                 Total (n=2882)   Women (n=754)   Men (n=2128)   *P* Value   Age ≤65 Years (n=1091)   Age \>65 Years (n=1791)   *P* Value
  ---------------------------------------------------------------------------- ---------------- --------------- -------------- ----------- ------------------------ ------------------------- -----------
  Hematoma requiring evacuation/transfusion[\*](#tf4-1){ref-type="table-fn"}   21 (0.73%)       7 (0.93%)       14 (0.66%)     0.45        3 (0.27%)                18 (1.01%)                0.03
  Tamponade[\*](#tf4-1){ref-type="table-fn"}                                   24 (0.83%)       14 (1.89%)      10 (0.47%)     \<0.001     11 (1.01%)               13 (0.73%)                0.42
  Death[\*](#tf4-1){ref-type="table-fn"}                                       21 (0.73%)       6 (0.80%)       15 (0.70%)     0.80        4 (0.37%)                17 (0.95%)                0.07
  Device reimplantation[†](#tf4-2){ref-type="table-fn"}                        68 (2.36%)       17 (2.25%)      51 (2.40%)     0.83        23 (2.11%)               45 (2.51%)                0.49
  Device-related infection[†](#tf4-2){ref-type="table-fn"}                     36 (1.25%)       10 (1.33%)      26 (1.22%)     0.82        16 (1.47%)               20 (1.12%)                0.41
  Mechanical complication requiring revision[†](#tf4-2){ref-type="table-fn"}   150 (5.2%)       46 (6.10%)      104 (4.89%)    0.20        51 (4.67%)               99 (5.53%)                0.32
  Any nonfatal complication                                                    225 (7.81%)      79 (10.48%)     146 (6.86%)    0.001       75 (6.87%)               150 (8.38%)               0.15
  Any complication (including death within 30 days)                            241 (8.36%)      81 (10.74%)     160 (7.52%)    0.006       78 (7.15%)               163 (9.10%)               0.07

Ascertained over 30 days after ICD implantation.

Ascertained over 90 days after ICD implantation.

###### 

Rates of Device-Related Complications by Sex and Age Stratified by Device Type

  Device Type   Total (n=2882)   Women (n=754)   Men (n=2128)   *P* Value   Age ≤65 Years (n=1091)   Age \>65 Years (n=1791)   *P* Value
  ------------- ---------------- --------------- -------------- ----------- ------------------------ ------------------------- -----------
  All devices   241 (8.36%)      81 (10.74%)     160 (7.52%)    0.006       78 (7.15%)               163 (9.10%)               0.07
  Single lead   43 (4.63%)       15 (6.91%)      28 (3.93%)     0.07        18 (3.79%)               25 (5.51%)                0.21
  Dual lead     87 (8.34%)       23 (10.00%)     64 (7.87%)     0.30        26 (7.58%)               61 (8.71%)                0.53
  CRT-D         111 (12.20%)     43 (14.01%)     68 (11.28%)    0.23        34 (12.45%)              77 (12.09%)               0.88

CRT-D indicates cardiac resynchronization therapy with defibrillator.

###### 

Rates of Individual Device-Related Complications Stratified by Device Type

  Complication                                                                 Total (n=2882)   Single Lead (n=929)   Dual Lead (n=1043)   CRT-D (n=1005)   *P* Value
  ---------------------------------------------------------------------------- ---------------- --------------------- -------------------- ---------------- -----------
  Hematoma requiring evacuation/transfusion[\*](#tf6-2){ref-type="table-fn"}   21 (0.73%)       4 (0.43%)             8 (0.77%)            9 (0.99%)        0.37
  Tamponade[\*](#tf6-2){ref-type="table-fn"}                                   24 (0.83%)       1 (0.11%)             11 (1.05%)           12 (1.32%)       0.01
  Death[\*](#tf6-2){ref-type="table-fn"}                                       21 (0.73%)       1 (0.11%)             9 (0.86%)            11 (1.21%)       0.02
  Device reimplantation[†](#tf6-3){ref-type="table-fn"}                        68 (2.36%)       12 (1.29%)            19 (1.82%)           37 (4.07%)       \<0.001
  Device-related infection[†](#tf6-3){ref-type="table-fn"}                     36 (1.25%)       9 (0.97%)             16 (1.53%)           11 (1.21%)       0.54
  Mechanical complication requiring revision[†](#tf6-3){ref-type="table-fn"}   150 (5.2%)       26 (2.80%)            48 (4.60%)           76 (8.35%)       \<0.001
  Any nonfatal complication                                                    225 (7.81%)      43 (4.63%)            78 (7.48%)           104 (11.43%)     \<0.001
  Any complication (including death within 30 days)                            241 (8.36%)      43 (4.63%)            87 (8.34%)           111 (12.20%)     \<0.001

CRT-D indicates cardiac resynchronization therapy with defibrillator.

Ascertained over 30 days after ICD implantation.

Ascertained over 90 days after ICD implantation.

Age and Sex Interactions With Measures of Heart Failure Status
--------------------------------------------------------------

Differences in study outcomes were stratified by NYHA symptom status, LVEF, and etiology of LVSD when the principal age or sex relationship was significant (Figures[1A](#fig01){ref-type="fig"} through [1C](#fig01){ref-type="fig"} and [2A](#fig02){ref-type="fig"} and [2B](#fig02){ref-type="fig"}). The interactions between sex and these heart failure characteristics were not statistically significant, with 2 exceptions. First, women had a higher risk of complications compared with men in the stratum of patients with NYHA I to II symptoms (women versus men: HR 1.94, 95% CI 1.26 to 3.01) versus those with III to IV symptoms (HR 1.03, 95% CI 0.68 to 1.57; sex--NYHA interaction, *P*=0.03) ([Figure 1C](#fig01){ref-type="fig"}). Second, older patients had a higher risk of heart failure hospitalizations compared with younger patients in the stratum of patients with ischemic cardiomyopathy (aged \>65 versus ≤65 years: HR 1.46, 95% CI 1.15 to 1.85) versus those with nonischemic cardiomyopathy (HR 1.03, 95% CI 0.80 to 1.34; age--etiology interaction, *P*=0.05) ([Figure 2B](#fig02){ref-type="fig"}).

![Outcomes comparing women with men in strata according to NYHA symptom status, LVEF, and etiology of left ventricular systolic dysfunction (A, mortality; B, heart failure hospitalization; C, complications). HR \<1 indicates lower risk in women compared with men. All interaction terms are not significant except for the interaction between sex and NYHA in the complications model (C, *P*=03). HR indicates hazard ratio; LVEF, left ventricular ejection fraction; NIDCM, nonischemic dilated cardiomyopathy; NYHA, New York Heart Association; OR, odds ratio.](jah30004-e002005-f1){#fig01}

![Outcomes comparing patients aged \>65 years compared with those aged ≤65 years in strata according to NYHA symptom status, LVEF, and etiology of left ventricular systolic dysfunction (A, mortality; B, heart failure hospitalization). HR \>1 indicates a higher risk in patients aged \>65 years compared with younger patients. All interaction terms are not significant except for the interaction between age and etiology (nonischemic vs ischemic) in the hospitalizations model (B, *P*=0.05). HR indicates hazard ratio; LVEF, left ventricular ejection fraction; NIDCM, nonischemic dilated cardiomyopathy; NYHA, New York Heart Association.](jah30004-e002005-f2){#fig02}

Discussion
==========

In this study of a community-based cohort of patients with LVSD receiving an ICD for primary prevention, the burden of adverse outcomes, including death and hospitalization for heart failure over 3 years, was substantial and varied by age and sex. After accounting for differences in other characteristics, women had a lower risk of death and hospitalization for heart failure than men and higher risks of device-related complications. Older patients had higher risks of death and heart failure--related hospitalizations but not for all-cause hospitalizations. The age and sex differences in these outcomes generally did not vary by severity of heart failure symptoms, etiology of systolic dysfunction, or LVEF. The results of this study provide estimates of the risks of several clinically important adverse outcomes in contemporary practice. These data can inform the decision-making process and the design of trials of therapies in the growing population of patients receiving ICD therapy. Furthermore, the results of this multisite longitudinal study provide greater context for understanding sex- and age-related differences in this high-risk patient population.

The results of this observational study provide estimates of the risks of adverse outcomes in a demographically diverse population with high rates of guideline-recommended medical therapies for LVSD receiving an ICD for primary prevention with long-term follow-up for a wide variety of outcomes important to patients. Although several prior studies have focused on outcomes in this population, these studies have been limited by the lack of heterogeneity of the study population with respect to age or sex, the lack of follow-up beyond 1 year, and the availability of follow-up in patients across a limited age spectrum or by the inability to characterize outcomes other than death.[@b6]--[@b11] The results of this study suggest that in this diverse population of patients with systolic dysfunction who are treated with an ICD, the risks of adverse outcomes other than death are high, including a substantial burden of hospitalization across patient strata during long-term follow-up after device implantation.

The randomized trials of ICD therapy for primary prevention that underlie current guideline recommendations enrolled younger patients and few women.[@b2]--[@b4] Moreover, because a number of these trials were published \>2 decades ago, therapy for patients with heart failure has evolved substantially, the estimates of outcomes from these trials are of limited value, particularly in these important demographic groups. Although a number of observational studies have focused on outcomes after ICD implantation, in some cases these studies are also limited because of a lack of contemporary data, relatively limited follow-up, or a primary focus on death. Because of the diversity of the CVRN cohort, we were able to characterize sex- and age-specific risks of death, hospitalization, and device-related complications.

Studies of sex differences in clinically meaningful long-term outcomes after ICD placement have been conflicting, perhaps in part due to differences in study design, population, time period, and length of follow-up. Post hoc analyses of individual randomized trials have shown variable differences in mortality based on patient sex[@b19]--[@b21]; a meta-analysis of the major primary prevention trials found no sex-based differences in mortality between men and women.[@b22] Because of the differences between the populations enrolled in trials and those receiving ICD therapy in practice,[@b5] observational studies provide complementary information. Although the finding of a lower risk of death among women in our study is similar to that of a prior single-center study of women receiving primary-prevention devices, other studies have found no mortality differences.[@b7],[@b8],[@b12],[@b23] Prior studies, however, have been heterogeneous and have included patients receiving ICDs for both primary and secondary prevention or focused on older patients with a shorter time frame of follow-up, possibly influencing the frequency and correlates of adverse outcomes. The relationship between sex and hospitalizations has not been the frequent focus of other investigations; although a recent study from the NCDR identified a higher risk of hospitalizations for women, this study was conducted in an older cohort followed for 6 months and did not include cardiac resynchronization therapy devices.[@b12] Women have been noted to be at consistently higher risk for ICD-related complications.[@b12],[@b23],[@b24] The current study provides an estimate of the magnitude of these differences in a contemporary population, including the differences across the spectrum of the devices commonly used in clinical practice.

Not surprisingly, age has been identified as an important determinant of adverse outcomes in a wide variety of cardiovascular conditions; however, the data generated in this study are important because they provide contemporary estimates of the magnitude of the age-associated risks for a broad variety of outcomes with long-term follow-up. In a cohort from Ontario, Canada, including patients receiving both primary and secondary prevention ICD therapy, advanced age was an important risk factor for death and hospitalization.[@b25] The death rates in that cohort were somewhat lower than in this study. Although the cardiovascular characteristics of the populations of our study and that from Ontario were similar, the burden of comorbidities was greater in the CVRN cohort. In addition, the follow-up in the current study was, on average \>1 year longer. Rates of all-cause and heart failure--related hospitalizations were not reported in the Ontario study, limiting comparisons with our study. Despite observed increases in the risk of death with older age, analyses of data from published randomized trials have not identified clear evidence that effectiveness of ICD therapy among eligible patients is sensitive to age.[@b26] Nonetheless, the rates of adverse outcomes in the demographically diverse population of this study provide a perspective in terms of what patients might expect after ICD implantation and emphasize the need for additional effective therapies and treatment strategies to reduce the longer term risks of death or hospitalization.

Reasons for age and sex differences in outcomes after ICD implantation are not clear. With regard to sex, proposed mechanisms range from inherent biological differences to differences in the severity of heart failure in patients receiving this therapy. Some data suggest, for example, important biological differences between men and women that could result in lower risks of death associated with LVSD in women.[@b27] This sex variability could also reflect differences in heart failure severity or the extent and etiology of LVSD of patients who are selected for ICD therapy. Women, for example, might have better survival if they have less advanced heart failure than men when they are identified for ICD therapy; however, in our patient cohort, this was not the case because a higher proportion of women in the CVRN cohort had advanced heart failure symptoms. With regard to age, older patients may have competing causes of death that would render ICDs less effective, especially in those with less severe heart failure. The age and sex differences observed in this study persisted after accounting for a wide variety of factors and did not vary according to the burden of heart failure symptoms, severity of LVSD, or etiology of heart failure. Consequently, alternative explanations for these demographic differences in outcomes warrant exploration. Better understanding of the underlying reasons for these differences could refine the identification of patients who might derive maximal benefit from ICD therapy.

Certain factors should be considered in the interpretation of the results of this study. Because all patients received an ICD, it was not possible to estimate differences in outcomes associated with the ICD therapy itself. In an observational context, identifying suitable untreated control groups is challenging because of the risk of substantial confounding by indication. Nonetheless, characterizing the risks of adverse outcomes is pertinent to the growing population of patients receiving ICD therapy for primary prevention in contemporary practice. In addition, the study sample was identified from integrated health plans and thus may not be representative of some patient populations such as the uninsured; however, the population was demographically diverse, with robust representation of women, racial and ethnic minorities, and elderly patients and similar to larger US populations of patients receiving an ICD for primary prevention.[@b5]

In this cohort study of a diverse population of patients with LVSD receiving an ICD for primary prevention, the burden of adverse outcomes in the 3 years following device implantation was substantial and varied importantly by age and sex. Observed age and sex differences were generally consistent across the spectrum of heart failure symptoms, left ventricular systolic function, and heart failure etiology. The risks of death, hospitalization, and device-related complications delineated in this study are important to the large population of patients with LVSD who are considering ICD therapy for primary prevention, to the clinicians caring for them, and to investigators interested in understanding the risks of clinically meaningful outcomes in the growing population of patients receiving this potentially life-saving therapy.
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